See more : Lords Group Trading PLC (LORD.L) Income Statement Analysis – Financial Results
Complete financial analysis of Quest Diagnostics Incorporated (DGX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quest Diagnostics Incorporated, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Tinna Trade Limited (TINNATFL.BO) Income Statement Analysis – Financial Results
- Avantax, Inc. (AVTA) Income Statement Analysis – Financial Results
- The Westaim Corporation (WED.V) Income Statement Analysis – Financial Results
- Longchen Paper & Packaging Co., Ltd. (1909.TW) Income Statement Analysis – Financial Results
- JPMorgan Chase & Co. (JPM-PC) Income Statement Analysis – Financial Results
Quest Diagnostics Incorporated (DGX)
Industry: Medical - Diagnostics & Research
Sector: Healthcare
Website: https://www.questdiagnostics.com
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.25B | 9.88B | 10.79B | 9.44B | 7.73B | 7.53B | 7.71B | 7.52B | 7.49B | 7.44B | 7.15B | 7.38B | 7.51B | 7.37B | 7.46B | 7.25B | 6.70B | 6.27B | 5.50B | 5.13B | 4.74B | 4.11B | 3.63B | 3.42B | 2.21B | 1.46B | 1.53B | 1.62B |
| Cost of Revenue | 6.29B | 6.45B | 6.58B | 5.80B | 5.04B | 4.93B | 4.72B | 4.62B | 4.66B | 4.64B | 4.33B | 4.36B | 4.40B | 4.32B | 4.32B | 4.26B | 3.97B | 3.70B | 3.26B | 2.99B | 2.77B | 2.43B | 2.15B | 1.97B | 1.32B | 813.90M | 875.50M | 1.01B |
| Gross Profit | 2.96B | 3.43B | 4.21B | 3.63B | 2.69B | 2.61B | 2.99B | 2.90B | 2.84B | 2.80B | 2.82B | 3.02B | 3.12B | 3.05B | 3.13B | 2.99B | 2.74B | 2.57B | 2.25B | 2.14B | 1.97B | 1.68B | 1.48B | 1.45B | 886.20M | 644.70M | 653.20M | 605.42M |
| Gross Profit Ratio | 32.00% | 34.74% | 39.02% | 38.50% | 34.80% | 34.59% | 38.79% | 38.58% | 37.85% | 37.63% | 39.46% | 40.88% | 41.48% | 41.41% | 42.03% | 41.29% | 40.79% | 41.04% | 40.82% | 41.66% | 41.57% | 40.79% | 40.69% | 42.49% | 40.19% | 44.20% | 42.73% | 37.46% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -15.00K | 27.00K | -18.00K | -34.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.62B | 1.87B | 1.73B | 1.55B | 1.46B | 1.42B | 1.75B | 1.68B | 1.68B | 1.73B | 1.70B | 1.75B | 1.81B | 1.71B | 1.75B | 1.74B | 1.61B | 1.43B | 1.26B | 1.23B | 1.17B | 1.07B | 1.02B | 1.00B | 643.40M | 481.60M | 502.10M | 495.32M |
| Other Expenses | 0.00 | 131.00M | 101.00M | 112.00M | 1.00M | -8.00M | 16.00M | -48.00M | -143.00M | 4.00M | 8.00M | 6.70M | 305.79M | 48.47M | 27.04M | 33.98M | 30.87M | 10.91M | 20.49M | 6.70M | 8.20M | 8.37M | 46.11M | 134.30M | 90.80M | 68.80M | 76.40M | 711.38M |
| Operating Expenses | 1.76B | 2.01B | 1.83B | 1.66B | 1.46B | 1.50B | 1.83B | 1.74B | 1.77B | 1.82B | 1.82B | 1.82B | 2.12B | 1.76B | 1.77B | 1.77B | 1.64B | 1.44B | 1.28B | 1.23B | 1.17B | 1.08B | 1.06B | 1.14B | 734.20M | 550.40M | 578.50M | 1.21B |
| Cost & Expenses | 7.94B | 8.46B | 8.41B | 7.47B | 6.50B | 6.43B | 6.54B | 6.36B | 6.43B | 6.45B | 6.15B | 6.18B | 6.52B | 6.07B | 6.10B | 6.03B | 5.61B | 5.14B | 4.54B | 4.23B | 3.94B | 3.52B | 3.22B | 3.10B | 2.05B | 1.36B | 1.45B | 2.22B |
| Interest Income | 11.00M | 10.00M | 1.00M | 3.00M | 5.00M | 2.00M | 2.00M | 1.00M | 1.00M | 3.00M | 3.00M | 3.00M | 2.77M | 1.41M | 2.52M | 5.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 163.00M | 138.00M | 151.00M | 163.00M | 175.00M | 167.00M | 151.00M | 143.00M | 153.00M | 164.00M | 159.00M | 164.70M | 170.60M | 146.10M | 144.10M | 185.48M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 439.00M | 437.00M | 408.00M | 361.00M | 329.00M | 309.00M | 270.00M | 249.00M | 304.00M | 314.00M | 283.00M | 286.60M | 281.10M | 254.00M | 256.70M | 264.60M | 237.88M | 197.40M | 176.12M | 168.73M | 153.90M | 131.39M | 147.73M | 134.30M | 90.80M | 68.80M | 76.40M | 99.10M |
| EBITDA | 1.73B | 1.82B | 3.16B | 2.41B | 1.59B | 1.40B | 1.45B | 1.48B | 1.56B | 1.30B | 1.79B | 1.52B | 1.30B | 1.59B | 1.63B | 1.50B | 1.33B | 1.33B | 1.18B | 1.05B | 950.36M | 723.84M | 559.12M | 452.11M | 242.80M | 163.10M | 151.10M | -502.19M |
| EBITDA Ratio | 18.72% | 18.31% | 29.27% | 25.52% | 20.45% | 18.67% | 18.82% | 18.10% | 20.82% | 17.85% | 18.42% | 20.58% | 17.38% | 21.43% | 22.12% | 21.25% | 19.88% | 21.27% | 21.20% | 21.07% | 19.99% | 17.17% | 15.37% | 13.32% | 14.46% | 11.66% | 13.34% | -31.07% |
| Operating Income | 1.26B | 1.43B | 2.38B | 1.97B | 1.23B | 1.10B | 1.17B | 1.28B | 1.40B | 983.00M | 1.48B | 1.20B | 995.00M | 1.30B | 1.36B | 1.22B | 1.09B | 1.13B | 968.11M | 901.44M | 795.43M | 592.45M | 411.39M | 317.82M | 152.00M | 94.30M | 74.70M | -601.28M |
| Operating Income Ratio | 13.64% | 14.45% | 22.07% | 20.89% | 15.93% | 14.62% | 15.11% | 16.99% | 18.67% | 13.22% | 20.64% | 16.27% | 13.25% | 17.58% | 18.23% | 16.86% | 16.28% | 17.99% | 17.59% | 17.58% | 16.79% | 14.42% | 11.34% | 9.29% | 6.89% | 6.47% | 4.89% | -37.20% |
| Total Other Income/Expenses | -132.00M | -193.00M | 218.00M | -87.00M | -155.00M | -175.00M | -135.00M | -142.00M | -101.00M | -134.00M | 192.00M | -133.00M | -130.77M | -99.28M | -131.18M | -203.42M | -178.93M | -94.73M | -57.66M | -76.55M | -58.66M | -50.07M | -114.80M | -116.84M | -137.60M | -40.40M | -93.80M | -74.92M |
| Income Before Tax | 1.13B | 1.24B | 2.60B | 1.88B | 1.08B | 926.00M | 1.03B | 1.09B | 1.10B | 849.00M | 1.35B | 1.07B | 856.30M | 1.18B | 1.23B | 1.02B | 912.40M | 1.03B | 910.45M | 835.13M | 737.80M | 542.38M | 332.60M | 200.98M | 14.40M | 53.90M | -19.10M | -676.20M |
| Income Before Tax Ratio | 12.21% | 12.50% | 24.09% | 19.96% | 13.93% | 12.30% | 13.36% | 14.45% | 14.72% | 11.42% | 18.86% | 14.47% | 11.40% | 16.07% | 16.47% | 14.06% | 13.61% | 16.48% | 16.54% | 16.29% | 15.57% | 13.20% | 9.17% | 5.87% | 0.65% | 3.70% | -1.25% | -41.84% |
| Income Tax Expense | 248.00M | 264.00M | 597.00M | 460.00M | 247.00M | 182.00M | 241.00M | 429.00M | 373.00M | 262.00M | 500.00M | 401.90M | 349.00M | 425.50M | 460.40M | 386.80M | 358.57M | 407.58M | 364.18M | 335.93M | 301.08M | 220.22M | 148.69M | 96.03M | 15.70M | 27.00M | 3.20M | -50.24M |
| Net Income | 854.00M | 946.00M | 2.00B | 1.43B | 858.00M | 736.00M | 772.00M | 645.00M | 709.00M | 556.00M | 849.00M | 555.70M | 470.60M | 720.90M | 729.10M | 581.50M | 339.94M | 586.42M | 546.28M | 499.20M | 436.72M | 322.15M | 162.30M | 102.05M | -3.40M | 26.90M | -22.30M | -625.96M |
| Net Income Ratio | 9.23% | 9.57% | 18.49% | 15.16% | 11.11% | 9.77% | 10.01% | 8.58% | 9.46% | 7.48% | 11.88% | 7.53% | 6.27% | 9.78% | 9.78% | 8.02% | 5.07% | 9.35% | 9.93% | 9.74% | 9.22% | 7.84% | 4.47% | 2.98% | -0.15% | 1.84% | -1.46% | -38.73% |
| EPS | 7.59 | 8.12 | 15.90 | 10.68 | 6.38 | 5.41 | 5.63 | 4.58 | 4.92 | 3.83 | 5.58 | 3.49 | 2.95 | 4.08 | 3.91 | 2.99 | 1.76 | 2.98 | 2.71 | 2.45 | 2.11 | 1.67 | 0.87 | 0.57 | -0.03 | 0.23 | -0.19 | -5.33 |
| EPS Diluted | 7.52 | 7.98 | 15.53 | 10.52 | 6.29 | 5.29 | 5.50 | 4.51 | 4.87 | 3.81 | 5.54 | 3.46 | 2.92 | 4.05 | 3.87 | 2.97 | 1.74 | 2.94 | 2.66 | 2.35 | 2.02 | 1.62 | 0.83 | 0.54 | -0.03 | 0.22 | -0.19 | -5.33 |
| Weighted Avg Shares Out | 112.00M | 116.00M | 125.00M | 134.00M | 134.00M | 136.00M | 137.00M | 140.00M | 144.00M | 145.00M | 152.00M | 158.60M | 158.70M | 175.70M | 185.90M | 194.30M | 193.24M | 196.99M | 201.83M | 203.75M | 206.97M | 192.91M | 186.56M | 179.04M | 136.00M | 119.56M | 115.84M | 117.45M |
| Weighted Avg Shares Out (Dil) | 113.00M | 118.00M | 128.00M | 136.00M | 136.00M | 139.00M | 140.00M | 142.00M | 145.00M | 145.00M | 153.00M | 160.10M | 160.20M | 177.30M | 187.80M | 196.00M | 195.26M | 199.54M | 205.53M | 212.42M | 216.20M | 199.48M | 195.55M | 188.99M | 136.00M | 120.90M | 116.15M | 117.45M |
Quest Diagnostics' (DGX) New Study Exposes Alarming Data on STI
Quest Diagnostics' (DGX) joint study with the University of Alabama finds pregnant women undertested for STIs, raising serious concerns on maternal and newborn health.
questhealth.com Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies
Lab tests offer insights for individuals who may experience inadequate intake of essential nutrients due to dietary restrictions, certain prescription medications, or chronic health conditions SECAUCUS, N.J. , Aug. 15, 2024 /PRNewswire/ -- Micronutrients are essential vitamins and minerals that...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Aug. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.75 per share, payable on October 21, 2024 to shareholders of record of Quest Diagnostics...
Should Value Investors Buy Quest Diagnostics (DGX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong...
Quest Diagnostics (DGX) Gains From Innovation, Customer Wins
A key driver in Brain Health growth is Quest Diagnostics' (DGX) Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF Tests for diagnosing and monitoring.
Should Quest Diagnostics (DGX) be in Your Portfolio Now?
Quest Diagnostics' (DGX) robust base business performance instills optimism for long-term growth.
Pregnant Women Undertested for STIs, Finds Quest Diagnostics Health Trends® Study of Over 4 Million Pregnancies
One in three women who tested positive for chlamydia or gonorrhea while pregnant were not retested before giving birth, despite potential to transmit infections to newborns SECAUCUS, N.J. , Aug. 12, 2024 /PRNewswire/ -- A new study by researchers from...
Quest Diagnostics Incorporated (DGX) Hit a 52 Week High, Can the Run Continue?
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Quest Diagnostics Named a "Best Place to Work for Disability Inclusion" for Seventh Straight Year
Quest achieves top score of 100 on 2024 Disability Equality Index® Best Places to Work for Disability Inclusion SECAUCUS, N.J. , Aug. 1, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced it has been...
4 Stocks to Watch From a Challenging Outpatient Home Health Industry
Despite the macroeconomic challenges, dependence on telehealth and AI dominance are likely to drive the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, EHC and ADUS are well-poised to gain.
Source: https://incomestatements.info
Category: Stock Reports